中文摘要：

对 Mycobacterium bovis 的当前可得到的疫苗，肺结核的原因的代理人，别提供可靠功效，因此对有改进功效的一支新奇疫苗有需要。这里，我们使用蛋白质 transduction 技术交付直接表示 mycobacterial 抗原指向房间的 DNA 疫苗。我们使用了包括 VP22 的领域(PTD ) 蛋白质从 Marek 的疾病病毒 serotype 结合的各种各样的蛋白质 transduction 1 (MDV-1 ) ，作为为编码抗原的 DNA 构造的交货系统，早能分泌的 antigenic target-6 kDa (ESAT-6 ) 蛋白质和文化过滤蛋白质 10 (CFP-10 ) M。bovis。真核细胞的表示 plasmid pZ106，编码抗原 ESAT-6 和 CFP-10，结合了到各种各样的 PTD，被用来构造试验性的准备。我们的调查结果与 CFP-10 独自或在联合表明了那 VP22 : ESAT-6 熔化蛋白质能传播进包围 transfected 房间的房间单层的所有原子核。而激活 trans transcriptional PTD 出现了，熔化蛋白质和 8R 肽的有限交货是不能的交付熔化蛋白质进任何 untransfected 房间。我们证明了有熔化到 VP22 的准备的那免疫导致更高的抗体和干扰素 -- titer (P < 0.05 ) 。一起拿，我们的结果证明 MDV-1 VP22 用 DNA 疫苗在基因治疗和免疫用作潜在的有免疫力的 enhancer，为 M 的预防提供一条新奇途径。bovis 感染。

英文摘要：

Currently available vaccines against Mycobacterium bovis, the causative agent of tuberculosis, do not provide reliable efficacy and there is therefore a need for a novel vaccine with improved efficacy. Here, we use protein transduction technology to deliver DNA vaccines expressing mycobacterial antigens directly to target cells. We used various protein transduction domain （PTD） proteins including the VP22 conjugate from Marek＇s disease virus serotype 1 （MDV-1）, as delivery systems for DNA constructs encoding the antigens early secretory antigenic target-6 kDa （ESAT-6） protein and culture filtrate protein 10 （CFP-10） of M. bovis. The eukaryotic expression plasmid pZl06, encoding antigens ESAT-6 and CFP-10, conjugated to various PTDs, was used to construct experimental preparations. Our findings demonstrated that VP22 alone or in combination with CFP-10：ESAT-6 fusion protein could spread into all the nuclei of the cell monolayer surrounding the transfected cells. Whereas trans-activating transcriptional PTD showed limited delivery of the fusion protein and 8R peptide was unable to deliver the fusion protein into any untransfected cells. We have demonstrated that immunization with a preparation fused to VP22 leads to a higher antibody and interferon-γ titer （P〈 0.05）. Taken together, our results demonstrated that MDV-1 VP22 serves as a potential immune enhancer in gene therapy and immunization using DNA vaccines, offering a novel approach for the prevention of M. bovis infection.